Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute ca...
Data could not be retrieved
ANEB | Peers | Sector | |
---|---|---|---|
Market Cap | 57.519 M | 122 M | 64.805 M |
Price % of 52 Week High | Premium | 27.6% | 62.2% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -0.9% | -0.7% |
1 Year Price Total Return | -51.2% | -66.2% | -11.5% |
Beta (5 Year) | -1.09 | 1.44 | 0.64 |
10Y DCF Revenue ExitView Updated 1 day ago |
5Y DCF Revenue ExitView Updated 1 day ago |
DuPont ROE AnalysisView Updated 4 days ago |
10Y Historical FinancialsView Updated 4 days ago |
5Y Historical FinancialsView Updated 4 days ago |
EV / EBIT MultiplesView Updated 1 day ago |
P/E MultiplesView Updated 1 day ago |
Price / Book MultiplesView Updated 1 day ago |
CAPM WACC ModelView Updated 21 hours ago |
10Y DCF EBITDA ExitView Updated 1 day ago |
10Y DCF Growth ExitView Updated 1 day ago |
5Y DCF EBITDA ExitView Updated 1 day ago |
5Y DCF Growth ExitView Updated 1 day ago |
Earnings Power ValueView Updated 1 day ago |
EV / EBITDA MultiplesView Updated 1 day ago |
Price / Sales MultiplesView Updated 1 day ago |
EV / Revenue MultiplesView Updated 1 day ago |
(USD in thousands) | Trailing Twelve Months | Fiscal Quarters | |||
---|---|---|---|---|---|
Period Ending | Jun-23 | Jun-24 | Dec-24 | Dec-23 | Dec-24 |
Income Statement | |||||
Revenue | |||||
Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
EBITDA | |||||
Balance Sheet | |||||
Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash Flow Statement | |||||
Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
Free Cash Flow | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 |